Blinatumomab, a bispecific T-cell engager targeting CD19 and CD3, has demonstrated efficacy in inducing MRD-negative remission in children with relapsed or refractory CD19+ pre-B ALL. Here, CD19 is linked to acute lymphoblastic leukemia.